Barclays
SGTX

Barclays’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Barclays’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-180
Closed -$2.18K – 5305
2023
Q1 		$2.18K Hold
180
– – ﹤0.01% 4885
2022
Q4 		$820 Hold
180
– – ﹤0.01% 5133
2022
Q3 		$1K Hold
180
– – ﹤0.01% 4729
2022
Q2 		$2K Sell
180
-210
-54% -$2.82K ﹤0.01% 4909
2022
Q1 		$8K Buy
+390
New +$8.69K ﹤0.01% 4643

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's SGTX Position: Q2 2023 in Review

Barclays sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 180 shares — an estimated $2.18K sold.

Barclays first reported a position in SGTX in Q1 2022 and held it in 5 quarters. The position peaked at $8K in Q1 2022. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

  • Barclays reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 180 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.18K.
  • Barclays first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
  • Barclays's Sigilon Therapeutics, Inc. Common Stock position peaked at $8K in Q1 2022.
  • 16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.